LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Erasca Inc

Erasca Inc

Cerrado

11.23 -3.44

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

11.17

Máximo

11.29

Métricas clave
By Trading Economics
Ingresos	-154M -183M
BPA	-0.6
Empleados	103
EBITDA	-5.3M -37M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+80.34% upside

Dividendos
By Dow Jones
Próximas Ganancias	10 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-53M 3.2B
Apertura anterior	14.67
Cierre anterior	11.23

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 may 2026, 23:46 UTC

Charlas de Mercado

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 may 2026, 23:45 UTC

Charlas de Mercado

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 may 2026, 23:42 UTC

Charlas de Mercado

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 may 2026, 23:34 UTC

Charlas de Mercado

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 may 2026, 23:11 UTC

Charlas de Mercado

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 may 2026, 22:26 UTC

Adquisiciones, fusiones, absorciones

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 may 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 may 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 may 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 may 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 may 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 may 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 may 2026, 22:11 UTC

Charlas de Mercado

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 may 2026, 22:04 UTC

Charlas de Mercado

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 may 2026, 08:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

23 may 2026, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 may 2026, 21:10 UTC

Ganancias

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 19:47 UTC

Ganancias

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 may 2026, 19:17 UTC

Charlas de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 may 2026, 19:10 UTC

Charlas de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 may 2026, 18:38 UTC

Charlas de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 may 2026, 18:35 UTC

Adquisiciones, fusiones, absorciones

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 may 2026, 18:09 UTC

Charlas de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 may 2026, 17:58 UTC

Charlas de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

80.34% repunte

Estimación a 12 Meses

Media 20.27 USD 80.34%

Máximo 30 USD

Mínimo 9 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Erasca Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.